In today's ACT Brief, we examine the FDA's multi-domain transparency priorities, why radiopharmaceutical trials need redesigned infrastructure, and how AI can make enrollment more predictable.
News|Podcasts|April 17, 2026
ACT Brief: Master Protocol Design Considerations, Early Predictive Data Integration, and Real-World Evidence as Regulatory Standard
Author(s)Andy Studna, Senior Editor
In today's ACT Brief, we explore biological and dosing considerations for basket trial designs, how human-relevant data earlier in development reduces late-stage failures, and FDA's shift toward single-trial approvals supported by real-world evidence.
This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.
- In part three of her video
interview , Mwango Kashoki, MD, MPH, senior vice president and global head of regulatory strategy at Parexel, examined biological, dosing, and population-level considerations sponsors must get right from the start when using basket and master protocol designs. Success depends on thoughtful target selection, dose optimization across conditions, and realistic patient population assumptions before enrollment begins. - In a new
Q&A , Jenna DiRito, PhD, COO and co-founder of Revalia Bio, discussed why traditional go/no-go models are breaking down and how human-relevant data generated earlier in development reduces uncertainty. Teams are answering questions about mechanism, safety, and biodistribution in human systems before clinical trials rather than waiting for late-stage failures to expose gaps. - In a new contributed
article from Pharmaceutical Executive, FDA's shift toward single-trial approvals supported by real-world evidence represents recognition that AI analytics can now convert fragmented RWD into regulatory-grade evidence. The transition requires building organizational capabilities to unify disparate data sources and apply rigorous study design before approvals, moving RWD integration from late-stage consideration to foundational development planning.
That's all for today's ACT Brief. Join us next week for more updates shaping clinical operations and drug development. Thanks for listening.
Related to this article
In today's ACT Brief, we examine FDA input sought on early-phase ibogaine protocols, why mixed outsourcing models spread faster than oversight infrastructure, and a major partnership for a rare kidney disease treatment.
In today's ACT Brief, we examine practical guidance for clinical operations teams beginning AI adoption, how hierarchical endpoints better reflect treatment benefit, and why early-stage program failures signal smarter pipeline management.
In today's ACT Brief, we examine how AI enables sponsors to pressure-test protocols before enrollment, HHS's multi-initiative effort to accelerate trial design and execution, and FDA approval expanding heart disease therapy to adolescents.
In today's ACT Brief, we examine AI's role as trial design advisor with human leadership, how to govern autonomous agents in regulated operations, and real-world outcomes from switching to oral weight-loss therapy.
In today's ACT Brief, we examine how data drives honest enrollment assumptions, why RWE infrastructure lags ambition, and the disconnect between FDA rulemaking and enforcement on compounded therapies.
In today's ACT Brief, we examine what AI simulations surface in trial design, how RBQM delivers measurable financial returns, and three new FDA-approved treatments across hair loss, movement disorder, and bone disease.
In today's ACT Brief, we examine how AI is surfacing endpoint options beyond traditional design thinking, why sponsor oversight of outsourced work often fails on inspection despite being robust in practice, and a new combination drug for advanced kidney cancer.
Trending on Applied Clinical Trials Online
1
FDA Releases Transparency Roadmap Outlining Disclosure Priorities Across Drug Development and Regulatory Review
2
FDA Seeks Public Input on Early-Phase Clinical Trial Design for Ibogaine
3
Beyond the Molecule: Why Radiopharmaceutical Trials Require a New Operating Model
4
Operation TrialBlazer Leveraging New and Anticipated US Policy Changes in Early Development
5